Does peripheral nerve stimulation produce a tingling sensation?

Most PNS programs produce a mild tingling (paresthesia) in the painful distribution that patients often describe as comfortable and controllable. Programming can be adjusted to favor more or less perceptible stimulation.

Peripheral Nerve Stimulation Hoffman Estates IL

I see this in my practice every week: a patient with a single, named, well-localized nerve pain — the back of the head after a whiplash, the groin after a hernia repair, a shoulder that hasn’t been right since a labral surgery, a foot that burns where the saphenous nerve runs. They’ve been told they need a spinal cord stimulator. Sometimes that’s the right answer. Often, there is a smaller, more elegant option upstream. It’s called peripheral nerve stimulation, and for the right patient it can resolve focal neuropathic pain without ever entering the spinal canal — sometimes with a device that comes out at 60 days and leaves nothing behind. As a triple board-certified pain medicine specialist (ABA Anesthesiology, ABA Pain Medicine, ABIPP), I implant peripheral nerve stimulators in my Hoffman Estates, Illinois practice as the least-invasive end of the neuromodulation ladder. The honest version is this: PNS is the most under-used tool in modern pain medicine — and for the right patient, it’s the first one I reach for.

What peripheral nerve stimulation actually is

Peripheral nerve stimulation places a thin electrical lead directly next to a specific peripheral nerve — somewhere out in the arm, leg, trunk, or scalp — and delivers low-voltage signals that interrupt the pain message before it ever travels up the spinal cord. The lead does not enter the spinal canal. It sits under the skin or within muscle, hugging the target nerve, typically placed with ultrasound guidance (sometimes with fluoroscopy) in a procedure that takes about 20–45 minutes.

There are two clinically meaningful flavors of PNS, and the difference matters enormously to patients.

Temporary (percutaneous) PNS — the 60-day system. The SPRINT PNS System (SPR Therapeutics) is a percutaneous lead that stays in place for up to 60 days and is then withdrawn. There is no permanent implant. No battery. No generator. The lead exits the skin and connects to a small external stimulator the patient wears on a sticker on the skin or clipped to the waistband. After 60 days the lead is gently pulled out in clinic. The therapeutic effect, in the right indication, often outlasts the treatment — neuromodulation of the painful nerve appears to reset the pain pathway, and in many patients the relief is durable months and years after the device is gone. Yes, the irony isn’t lost on me: the least-invasive option can also be the most curative.

Permanent (implanted) PNS. The Bioness StimRouter (Bioventus) and the Nalu Neurostimulation System are FDA-approved permanent peripheral nerve stimulators. A thin lead is tunneled under the skin next to the target nerve, anchored, and connected to a small generator — for StimRouter, an externally worn patch on the skin powers the lead wirelessly; for Nalu, a small subcutaneous IPG is used. These systems stay in place indefinitely and are programmed for long-term focal neuropathic pain.

The choice between temporary and permanent PNS is one of the most important decisions I make on this page, and I’ll come back to it below.

Who is a candidate for peripheral nerve stimulation?

The patients I see succeed with PNS have a pain pattern with a single anatomical home. Strong candidates typically have:

Focal neuropathic pain in the distribution of one (sometimes two) named peripheral nerves — burning, electric, shooting, or stabbing in quality.
Occipital neuralgia — chronic head and upper-neck pain in the distribution of the greater or lesser occipital nerve, often after whiplash, surgery, or a structural cervical issue.
Post-amputation pain — phantom limb pain or stump neuroma pain after a lower-extremity or upper-extremity amputation.
Post-surgical neuropathic pain — persistent burning pain in the groin (ilioinguinal or genitofemoral nerve after hernia repair), the knee (saphenous or infrapatellar branch after knee surgery), the shoulder (suprascapular or axillary nerve after rotator-cuff or labral surgery), the chest wall (post-thoracotomy intercostal pain), or other identifiable focal regions.
Hemiplegic shoulder pain after stroke — an FDA-cleared SPRINT indication with strong supporting trial evidence.
A positive diagnostic nerve block — a temporary local anesthetic block of the suspected nerve that produced meaningful (often ≥50%) pain relief. This is the single best predictor of PNS success in my practice.
Failure of conservative care — physical therapy, neuropathic medications (gabapentin, pregabalin, duloxetine, topical compounds), and at least one targeted nerve block or steroid injection.
An anatomically accessible nerve that can be safely targeted with ultrasound or fluoroscopy without putting nearby vasculature or motor nerves at unacceptable risk.

I will be equally direct about who is not a PNS candidate. PNS is the wrong answer for diffuse, multi-region, or axial pain. If your pain is in your back and both legs, both feet, or shifts from place to place, peripheral nerve stimulation isn’t the tool — you need an SCS or, for a single dermatomal region, a DRG. If your pain has no clean anatomical home — no nerve you can name, no block that gave you relief — PNS is a poor bet and I won’t recommend it.

PNS is also not the right answer for active untreated infection, severe coagulopathy, severe untreated depression, or active substance use disorder. And for pain that comes from a structural problem that hasn’t been worked up — a torn rotator cuff that hasn’t seen orthopedics, a hernia recurrence that hasn’t been imaged — we deal with the structural problem first.

What usually fails before PNS

The patients who land in my office for a PNS conversation have almost always done the right things first. They’ve completed 6–12 weeks of physical therapy. They’ve tried gabapentin or pregabalin and either gotten partial relief or felt foggy and sedated. They’ve had targeted nerve blocks — an occipital block, an ilioinguinal block, a suprascapular block, a saphenous block — and the block helped for hours or days. They’ve sometimes had a surgical re-exploration (a neuroma excision, a hernia mesh removal) that didn’t fix the pain or made it worse. By the time PNS is on the table, the patient has exhausted the conservative ladder and we have very strong evidence — usually a diagnostic block that gave temporary relief — that the pain is coming from a specific, identifiable peripheral nerve.

That diagnostic clarity is the strongest predictor of PNS success.

The ASPN best-practice guidance — why PNS is moving up the ladder

You should know that peripheral nerve stimulation is no longer a fringe option. The American Society of Pain and Neuroscience (ASPN) best-practice consensus document (Deer et al., 2021) brought together the evidence, indications, and recommended technique for PNS across the major pain syndromes [J Pain Res 2021; PMID 34526815]. The document recommends PNS as a first-line neuromodulation option for several focal neuropathic conditions where it had previously been an afterthought — including occipital neuralgia, post-amputation pain, hemiplegic shoulder pain after stroke, and select post-surgical neuropathic syndromes. In a number of these indications, PNS is now considered upstream of SCS and DRG — meaning we should try the smaller, less-invasive option first.

That guidance is one of the reasons PNS volume in my practice has grown meaningfully in recent years. The technology has caught up with the clinical need.

The trial — and why “temp-then-gone” changes everything

PNS uses a trial framework, like SCS and DRG, but the trial mechanics depend on which system we’re considering.

For the SPRINT 60-day temporary system, the “trial” and the “treatment” are the same thing. This is the most important phrase on this page for the right patient. I place a thin lead under ultrasound guidance directly next to the target nerve in a 15–30 minute outpatient procedure under local anesthesia. The lead exits the skin and connects to a small external stimulator you wear on your skin or clip to your waistband. You go home the same day, and you wear the device for up to 60 days. Then I withdraw the lead in clinic — it takes about 30 seconds. In carefully selected patients, the pain relief outlasts the device. I have patients — including endurance athletes and active people who wanted nothing permanent in their body — who completed a 60-day SPRINT course for shoulder pain, had the lead pulled, and were still pain-free a year or more later. That is not a guarantee, and the durability data is still maturing — but for the right patient, the “temp-then-gone” pathway is one of the most patient-friendly tools in pain medicine.

For the Bioness StimRouter or Nalu permanent system, the trial looks more like SCS. I place a temporary percutaneous lead under ultrasound (or fluoroscopic) guidance, connect it to an external generator, and you wear the system for 7–10 days. If you achieve ≥50% pain reduction and meaningful functional improvement during the trial, we schedule the permanent implant. If you don’t, we remove the trial lead in the office and revisit the plan. As with SCS and DRG, the trial is a filter, not a formality.

What the procedure looks like

SPRINT placement day. You arrive at the office or outpatient surgery center. I review your imaging, your block history, and your trial goals one more time. You receive light sedation in some cases, local anesthesia for others — most SPRINT placements are done under local only. Under live ultrasound guidance, I identify the target nerve, advance a small introducer needle directly alongside it, and deploy the thin coiled lead. I confirm position by stimulating while you’re awake enough to tell me what you feel — we want stimulation in the painful distribution without motor contraction. The lead exits the skin, is taped securely, and connects to the external generator. The whole procedure typically takes 15–30 minutes. You go home the same day with detailed care instructions, a programmed external stimulator, and the manufacturer’s support line.

Permanent PNS implant day. For a StimRouter or Nalu permanent implant, the procedure takes 45–75 minutes under local anesthesia and light sedation, typically in an outpatient surgery setting. The lead is tunneled under the skin alongside the target nerve, anchored, and connected to its generator system. You go home the same day. Stitches and dressings come off at 7–14 days.

Intraoperative imaging. I use ultrasound for almost all PNS lead placements — it’s the right tool for soft-tissue work. Fluoroscopy is added when the anatomical target requires it (deeper trunk nerves, certain occipital placements).

Recovery and what to expect

SPRINT (temporary) recovery. Most patients are back to non-strenuous activity the day after placement. Keep the dressing site clean and dry — no swimming, no hot tubs, no soaking baths while the lead is in place. Showers are fine once the manufacturer instructions allow (typically 24–48 hours after placement, with the site covered). Light exercise — walking, stationary cycling, light strength work — is usually fine within a few days. Aggressive arm overhead motion or contact sport during a SPRINT shoulder course should be discussed case by case. After the 60 days, the lead is removed in clinic in about 30 seconds, and most patients return to full activity immediately.

Permanent PNS recovery. Similar restrictions to a small soft-tissue surgical procedure for the first 7–14 days at the implant site: no heavy lifting, no aggressive range-of-motion through the surgical field, no soaking. After the first 2 weeks, progressive return to activity — most patients are back to full activity by 4–6 weeks, with device programming refinements happening over the first few months. I have patients who run, cycle, lift weights, and train hard with permanent PNS systems in place. The lead is small, the generator footprint is small, and once healed, you barely know it’s there.

Risks — the honest list

PNS is at the safer end of the neuromodulation spectrum, but it is still a procedure with real risks. Common (1–5%): lead site irritation or skin reaction at the dressing/external generator, transient site infection (typically superficial, treated with oral antibiotics), lead migration or dislodgement (especially with the SPRINT temporary lead during the 60 days), and inadequate coverage requiring repositioning. Rare but serious (<1%): deeper soft-tissue infection, nerve injury (almost always temporary), bleeding/hematoma, device failure requiring revision, and — for permanent implants — pocket-related issues. There is no spinal canal entry, no risk of epidural hematoma, and no risk of dural puncture or spinal headache — that is one of PNS’s structural advantages over SCS and DRG. The international NACC consensus on bleeding and infection prevention applies broadly to neuromodulation [Deer et al., Neuromodulation 2017; PMID 27986601] — we screen anticoagulation, dental work, and active infection meticulously before any PNS procedure.

Alternatives and how I decide

This is the section that matters most. If you’ve been told you need a “stimulator,” PNS is increasingly the right first step for focal pain — but the choice isn’t automatic.

PNS vs. spinal cord stimulation (SCS). SCS is the right answer when pain is broad, axial, or bilateral — back plus both legs, complex multi-region distribution, or post-laminectomy syndrome where the pain map covers multiple dermatomes. PNS is the right answer when the pain is focal and named — one nerve, one anatomical home. If your pain involves the back, both legs, and the buttocks, I am not reaching for PNS. If your pain is in the groin after a hernia repair, the back of the head after a whiplash, or one shoulder after a labral surgery, PNS is often the right first step before we even discuss SCS. (Read more on the spinal cord stimulator page.)

PNS vs. DRG stimulation. This is the harder decision. DRG targets the cell bodies just outside the spinal cord; PNS targets the nerve out in the periphery. DRG is the better choice when the pain covers a whole dermatome — for example, the L4 distribution after a knee replacement, or the inguinal dermatome with CRPS-like features. PNS is the better choice when the pain is in a single named peripheral branch — occipital neuralgia, ilioinguinal neuralgia, suprascapular shoulder pain. PNS is less invasive (no spinal canal entry) and is a reasonable first step before DRG for many indications. If PNS fails, DRG remains on the table. (Read more on the DRG stimulation page.)

PNS vs. genicular RFA for knee pain. For chronic knee osteoarthritis pain in a patient who isn’t a surgical candidate, my default is genicular nerve block followed by genicular RFA — that’s the better-evidenced and lower-cost first step. PNS for knee pain comes into play for post-surgical neuropathic knee pain (after total knee replacement, ACL reconstruction, or other procedures where a specific peripheral nerve has been injured) rather than for osteoarthritic knee pain. The two procedures address different pain mechanisms. (Read more on the genicular nerve block & RFA page.)

PNS vs. nerve blocks or nerve cryoablation. Diagnostic nerve blocks are how we get to PNS in the first place — they confirm the target. Repeated therapeutic blocks can be a viable long-term plan for some patients, but they require ongoing clinic visits and the relief is typically short. PNS gives a more sustained answer when the block confirms a focal target but the relief never lasts. Cryoneurolysis (nerve freezing) is another option for select peripheral targets and is something we can discuss in consultation.

When I wouldn’t choose PNS. Diffuse or multi-region pain, axial low back pain alone, an unaddressed structural problem (rotator cuff tear, hernia recurrence, untreated cervical pathology), pain without a clean anatomical home, active infection, severe untreated depression or substance use, pregnancy, or a recent surgical site that needs more time to heal.

Insurance and prior authorization

PNS is covered by Medicare and most major commercial insurers in Illinois, but coverage rules vary meaningfully by device and indication. SPRINT 60-day temporary PNS has its own dedicated CPT code (CPT 64555 for percutaneous lead placement, plus device-specific HCPCS coding) and is covered by Medicare for several specific indications including hemiplegic shoulder pain after stroke, post-amputation pain, and certain post-surgical neuropathic conditions. Permanent PNS implants (StimRouter, Nalu) typically require documentation similar to SCS: ≥6 months of documented focal neuropathic pain, failure of conservative care, a positive diagnostic block, and in some cases a psychological evaluation. My office handles the prior authorization paperwork end-to-end — the clinical letter, the documentation packet, and the peer-to-peer call if the insurer requests one.

Frequently asked questions

How is peripheral nerve stimulation different from a spinal cord stimulator? PNS targets a single, named peripheral nerve out in the body — never entering the spinal canal. SCS sits in the epidural space and modulates the spinal cord broadly. PNS is the right answer when the pain has a single anatomical home; SCS is the right answer for broad or bilateral pain.

What is the SPRINT 60-day PNS system? SPRINT is an FDA-cleared temporary peripheral nerve stimulator. A thin lead is placed next to the target nerve in a brief outpatient procedure, you wear the external generator for up to 60 days, and then the lead is gently removed in clinic. In the right indication, the pain relief frequently outlasts the device — sometimes for many months or years.

What conditions is PNS approved for? Approved and commonly used indications include occipital neuralgia, post-amputation pain (phantom limb and stump neuroma), post-surgical neuropathic pain (groin, knee, shoulder, chest wall), hemiplegic shoulder pain after stroke, and other focal neuropathic syndromes. The ASPN 2021 best-practice consensus details the full clinical landscape.

Can I get an MRI with a permanent PNS system? The Bioness StimRouter and Nalu systems are MRI-conditional under specific scanner protocols. You receive a device identification card to share with imaging staff. The SPRINT temporary system is removed before any MRI is needed.

Does PNS produce a tingling sensation? Most PNS programs produce a mild tingling (paresthesia) in the painful distribution — patients often describe it as a comfortable, controllable sensation. Programming can be adjusted to favor more or less perceptible stimulation.

Will I feel the lead under my skin? Most patients do not feel the lead in normal daily activity. The permanent systems have a low subcutaneous profile, and the SPRINT temporary lead is so thin that most patients forget it’s there within a day or two.

If you’re considering peripheral nerve stimulation

If you have a single, named pain — the back of the head, the groin after a hernia, a shoulder that hasn’t been right since surgery, a foot in the distribution of one peripheral nerve — and you’ve been told the next step is a spinal cord stimulator, it’s worth a second opinion. Peripheral nerve stimulation is the smaller, more targeted option upstream, and for many of these patients it’s the right first move. Call my Hoffman Estates, Illinois office at (847) 981-3630 to schedule a consultation. I’ll review your imaging, your block history, and your pain pattern with you, walk you through the SPRINT vs. permanent decision, and — if PNS is the right answer — explain the trial or 60-day course in detail before anything is committed.